Share This Author
Antimitochondrial and other autoantibodies.
Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis.
Molecular mimicry in liver disease
Mitochondrial antibodies in primary biliary cirrhosis: Species and nonspecies specific determinants of M2 antigen
Sera from patients with primary biliary cirrhosis reacted with four major bands in beef heart mitochondria and ATPase extract when analyzed by immunoblot after sodium dodecyl sulfate‐polyacrylamide gel electrophoresis, indicating that M2 determinants, as defined by immunOBlot, are not identical with any ATPase subunit.
Mitochondrial antigens, molecular mimicry and autoimmune disease.
- H. Baum
- Biology, MedicineBiochimica et biophysica acta
- 24 May 1995
Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection.
Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of…
- P. Butler, J. Hamilton-miller, H. Baum, A. Burroughs
- Biology, MedicineBiochemistry and molecular biology international
- 1 March 1995
It is proposed that a bacterial trigger, possibly resulting from recurrent UTIs, is responsible for initiating an autoimmune response in a predisposed host because of a cross-reactivity between mitochondrial and bacterial antigens.
Association of integrated metabolic pathways with membranes. I. Glycolytic enzymes of the red blood corpuscle and yeast.
The role of iron in ferritin- and haemosiderin-mediated lipid peroxidation in liposomes.
Results indicate that, at pH 4.5, even in the absence of a reducing agent, iron is released from haemosiderin and can mediate oxidative damage to a lipid membrane.
Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.
- G. Watts, C. Castelluccio, C. Rice-Evans, N. Taub, H. Baum, P. Quinn
- Medicine, BiologyJournal of clinical pathology
- 1 November 1993
It is concluded that simvastatin may lower the plasma CoQ concentration and this may be greater than the reduction in cholesterol, and the possible adverse effect of simVastatin on the metabolism of CoQ may be clinically important and requires further study.